Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pivotal phase III trial of Viaskin Peanut epicutaneous immunotherapy in peanut-allergic children
2015-002461-37Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Sep 2015
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing Viaskin Peanut 250 µg with Placebo patch (2 arms). Primary endpoint: Primary responder rate. Started Sep 2015; status: completed.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2015-002461-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002461-37.